Alligator Bioscience Signs Agreement To Sell Mitazalimab to Biossil
(PR-inside.com) LUND, SE / ACCESS Newswire / October 31, 2026 / Alligator Bioscience (STO:ATORX)(Nasdaq Stockholm:ATORX), a biotechnology company whose principal asset is a financial interest in the HER2-targeting antibody program HLX22, today announced that it has signed an agreement to sell all rights and assets rela…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


